Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-02-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotech Co., Ltd. regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's name, registration number, specifications, approval, and related information. The document is short (844 characters) and serves as a formal public notice about regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-19 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Northland Biotechnology Co., Ltd. regarding the completion of industrial and commercial registration changes and the filing of the company's articles of association, along with obtaining a new business license. It references board resolutions and shareholder meetings related to capital changes and amendments to the articles of association. The document is short (984 characters) and primarily serves as a formal notice of these corporate changes and regulatory filings. It does not contain financial statements, detailed financial data, or management discussion and analysis. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is also not a report publication announcement since it contains substantive content about the registration completion. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-02-04 Chinese
关于更换持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a specific stock issuance project. It details personnel changes in the sponsor representatives and includes a brief biography of the new representative. There is no financial data, no report or presentation attached, and no mention of voting results or legal proceedings. This type of announcement relates to management or board-level information about company oversight and sponsorship roles. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on personnel change, not a full report or regulatory filing.
2024-02-04 Chinese
关于重组人肝细胞生长因子裸质粒注射液治疗Rutherford 5级（溃疡）严重下肢缺血性疾病Ⅲ期临床试验揭盲结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotech Co., Ltd. regarding the unblinding results of a Phase III clinical trial for a gene therapy drug. It provides preliminary data analysis results, trial design, and future steps. The document is relatively short (1324 characters) and focuses on clinical trial results and their impact on the company, without containing detailed financial data or comprehensive financial statements. It is not a full financial report, earnings release, or regulatory filing about financial performance. It is an announcement of clinical trial results, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a management or board change announcement, nor a capital or financing update. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial results and company disclosures that do not fit other specific categories.
2024-01-31 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司使用闲置募集资金进行现金管理、对控股子公司提供借款以实施募投项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Zhongtai Securities regarding the use of idle raised funds by Beijing Nuosiland Biotechnology Co., Ltd. It discusses the registration approval for a private placement of shares, the amount of funds raised, their storage, and the intended use of these funds including cash management and loans to subsidiaries. The document includes specific financial figures, regulatory references, and procedural approvals by the board and supervisory committee. It is not a full annual or interim report but a specialized audit or verification report related to the use of raised funds and compliance with regulatory requirements. The document length is 4118 characters, which is substantial and contains detailed financial and procedural information, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), as it is a standalone audit/verification report on the use of funds and compliance, not a full annual report or earnings release. Q1 2024
2024-01-24 Chinese
第六届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth board of directors' eighth meeting of Beijing Northland Biotechnology Co., Ltd. It includes meeting details, attendance, and multiple agenda items related to adjustments in the use of raised funds, cash management, loans to subsidiaries, storage of raised funds, and amendments to the company's articles of association and registered capital. The document is a formal announcement of board decisions rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on board resolutions and governance matters. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4245 characters, which is consistent with a detailed board meeting resolution announcement rather than a full report or a brief notice.
2024-01-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.